Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy. Issue 3 (9th February 2023)

• Record Type: Journal Article
• Authors: Wang, Chuhui; Chen, Jiaojiao; Yang, Bo; Li, Sihan; Zhang, Yiran; Chen, Lei; Wang, Taotao; Dong, Yalin
• Is Part Of: Pharmacotherapy. Volume 43:Issue 3(2023)
• Page Start: 180
• Page End: 188
• Publication Date: 2023-02-09
• Subjects: continuous renal replacement therapy -- critically ill -- exposure target -- individualized dosing -- vancomycin; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1002/phar.2771
• Languages: English
• ISSNs: 0277-0008

Abstract

Abstract: Study Objective: Few studies have been conducted to quantify the exposure target of vancomycin in intensive care unit (ICU) patients undergoing continuous renal replacement therapy (CRRT) and provide optimized dosage regimens. We aimed to determine vancomycin exposure target and dosing recommendations using data from an open database in critically ill patients undergoing CRRT. Design: A retrospective observational cohort study. Data Source: A large public database. Patients: The adult patients who received intravenous vancomycin and CRRT treatment in the database between 2017 and 2019 were reviewed to determine eligibility. A total of 180 patients with 1186 observations were included in the population pharmacokinetic (PPK) model development. The clinical efficacy of vancomycin was analyzed in 159 eligible patients. Methods: A PPK model was developed to estimate individual pharmacokinetic (PK) parameters. The area under the concentration‐time curve (AUC) was estimated by a Bayesian approach based on individual vancomycin concentrations. Multivariate logistic regression analyses were performed to identify the factors of clinical outcomes. Threshold of vancomycin exposure in predicting efficacy was identified via receiver operating characteristic (ROC) curve. Dosing recommendations were designed using Monte Carlo Simulations (MCS) based on the optimized exposure target. Measurements and Main Results: On covariate analysis, CRRT intensity significantly affected vancomycin PK. The AUC above 427 mg*h/L was the only significant predictor of clinical efficacy (adjusted odds ratio (aOR): 1.008, 95% confidence interval (CI): 1.004–1.011, p = 0.000). MCS indicated that vancomycin dosage regimens of 5 mg/kg q12h or 7.5 mg/kg q12h were recommended for patients with CRRT intensities of 20–25 mL/kg/h or 25.1–45 mL/kg/h, respectively. Conclusions: An AUC threshold of 427 mg*h/L (assuming the minimal inhibitory concentration (MIC) = 1 mg/L) was a recommended efficacy exposure target of vancomycin for critically ill patients undergoing CRRT. Vancomycin 5–7.5 mg/kg q12h is recommended as the initial dosage regimens for ICU patients undergoing CRRT.